Please use this identifier to cite or link to this item:
Title: Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C
Authors: Fialho, Renata 
Pereira, Marco 
Harrison, Neil 
Rusted, Jennifer 
Whale, Richard 
Keywords: Adult; Antiviral Agents; Coinfection; Depressive Disorder, Major; Drug Therapy, Combination; Female; HIV Infections; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Ribavirin
Issue Date: 2017
Citation: Fialho, R., Pereira, M., Harrison, N., Rusted, J., & Whale, R. (2017). Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Psychiatry Research, 253, 150-157. doi:10.1016/j.psychres.2017.03.049
Serial title, monograph or event: Psychiatry Research
Volume: 253
Abstract: In this prospective study, we examined new-onset major depressive disorder (MDD) and the differential expression of depressive symptoms in a sample of 132 HCV mono-infected and 40 HIV/HCV co-infected patients initiating pegylated interferon-based treatment, including protease inhibitor therapy. The semi-structured clinical interview (SCID-I) was used to assess MDD. Severity of depressive symptoms was assessed using the Hamilton Depression Rating Scale. Of the total sample, 60 patients (34.9%) developed SCID-I defined MDD during antiviral treatment. The proportion of HCV mono- and HIV/HCV patients developing MDD during treatment was not significantly different (37.9% vs. 25%; p=0.185). In both groups, there was a significant increase in HAMD total score from baseline to week 4, and a significant decrease between week 24 and 6 months post-treatment cessation. The greatest increase was observed in the symptoms of the neurovegetative syndrome. HCV mono-infected patients reported higher scores than co-infected patients, particularly impaired activity and somatic symptoms, but the differences were only significant at week 12. The finding that co-infected patients appear less vulnerable to the development of depressive symptoms during HCV treatment than HCV mono-infected patients warrants further exploration, including a thorough analysis of the biological and psychosocial factors associated with this emergence.
DOI: 10.1016/j.psychres.2017.03.049
Rights: openAccess
Appears in Collections:FPCEUC - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
2017 Depression Co_Infection HIV_HCV.pdf759.84 kBAdobe PDFView/Open
Show full item record


checked on May 29, 2020

Citations 10

checked on Sep 2, 2021

Page view(s) 20

checked on Oct 14, 2021


checked on Oct 14, 2021

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.